share_log

Senti Biosciences | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Senti Biosciences | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Senti Biosciences | PRE 14A：并购重组委托声明
美股sec公告 ·  05/17 17:23
Moomoo AI 已提取核心信息
Senti Biosciences, Inc. (Senti) has announced the upcoming 2024 Annual Meeting of Stockholders, scheduled to be held virtually on July 10, 2024. The meeting will address several key proposals, including the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and amendments to the company's Second Amended and Restated Certificate of Incorporation. These amendments involve the inclusion of an officer exculpation provision and the authorization of a reverse stock split of the company's common stock at a ratio determined by the board of directors. Additionally, the meeting will consider the adjournment of the Annual Meeting to solicit additional proxies if necessary. The board has fixed May 13, 2024, as the record date for stockholder entitlement to notice and voting rights at the meeting. Senti Biosciences is utilizing the SEC's 'Notice and Access' rule to furnish proxy materials online, reducing environmental impact and mailing costs. Stockholders will be able to vote electronically and submit questions during the virtual meeting.
Senti Biosciences, Inc. (Senti) has announced the upcoming 2024 Annual Meeting of Stockholders, scheduled to be held virtually on July 10, 2024. The meeting will address several key proposals, including the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and amendments to the company's Second Amended and Restated Certificate of Incorporation. These amendments involve the inclusion of an officer exculpation provision and the authorization of a reverse stock split of the company's common stock at a ratio determined by the board of directors. Additionally, the meeting will consider the adjournment of the Annual Meeting to solicit additional proxies if necessary. The board has fixed May 13, 2024, as the record date for stockholder entitlement to notice and voting rights at the meeting. Senti Biosciences is utilizing the SEC's 'Notice and Access' rule to furnish proxy materials online, reducing environmental impact and mailing costs. Stockholders will be able to vote electronically and submit questions during the virtual meeting.
森蒂生物科学公司（Senti）宣布即将举行的2024年年度股东大会，该会议定于2024年7月10日虚拟举行。会议将讨论几项关键提案，包括批准毕马威会计师事务所作为截至2024年12月31日的财政年度的独立注册会计师事务所，以及对该公司第二经修订和重述的公司注册证书的修订。这些修正包括纳入一项高管免责条款，并授权按董事会确定的比率对公司普通股进行反向分割。此外，如有必要，会议将考虑休会，以征集更多代理人。董事会已将2024年5月13日定为股东有权在会议上获得通知和投票权的记录日期。Senti Biosciences正在利用美国证券交易委员会的 “通知和访问” 规则在线提供代理材料，从而减少环境影响和邮寄成本。股东将能够在虚拟会议期间进行电子投票并提交问题。
森蒂生物科学公司（Senti）宣布即将举行的2024年年度股东大会，该会议定于2024年7月10日虚拟举行。会议将讨论几项关键提案，包括批准毕马威会计师事务所作为截至2024年12月31日的财政年度的独立注册会计师事务所，以及对该公司第二经修订和重述的公司注册证书的修订。这些修正包括纳入一项高管免责条款，并授权按董事会确定的比率对公司普通股进行反向分割。此外，如有必要，会议将考虑休会，以征集更多代理人。董事会已将2024年5月13日定为股东有权在会议上获得通知和投票权的记录日期。Senti Biosciences正在利用美国证券交易委员会的 “通知和访问” 规则在线提供代理材料，从而减少环境影响和邮寄成本。股东将能够在虚拟会议期间进行电子投票并提交问题。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息